Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Plus Therapeutics, Inc.

Market Cap 37.31M 32.37M 29.84M 27.96M 52.25M 3.57B 53.33M 356M 138M 1.72B 140M 137M 5.99B P/E Ratio 2026 *
-1.38x
P/E Ratio 2027 * -2.26x
Enterprise Value 37.31M 32.37M 29.84M 27.96M 52.25M 3.57B 53.33M 356M 138M 1.72B 140M 137M 5.99B EV / Sales 2026 *
5.93x
EV / Sales 2027 * 1.95x
Free-Float
98.37%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Plus Therapeutics, Inc.

1 day+0.56%
1 week-5.66%
Current month-6.87%
1 month-10.26%
3 months-29.54%
6 months-69.89%
Current year-57.68%
1 week 5.11
Extreme 5.11
5.86
1 month 5.05
Extreme 5.05
7.3
Current year 2.9
Extreme 2.9
15.32
1 year 2.9
Extreme 2.9
23.42
3 years 2.9
Extreme 2.9
86.14
5 years 2.9
Extreme 2.9
1,095
10 years 2.9
Extreme 2.9
429,377.68
Manager TitleAgeSince
Chief Executive Officer 64 2014-04-01
Director of Finance/CFO 52 2020-02-05
Chief Tech/Sci/R&D Officer - 2025-10-20
Director TitleAgeSince
Director/Board Member 64 2002-09-30
Chairman 77 2018-01-24
Director/Board Member 66 2019-12-31
Date Insider Type Main position Quantity % Market Cap.
05-13Free

Chairman

7,372 0.1074%
05-13Free

Director

8,972 0.1307%
05-13Free

Director

7,372 0.1074%
Change 5-day change 1-year change 3-year change Capi.($)
+0.56%-5.66%-34.30%-93.36% 37.31M
+0.66%+2.29%-14.86%-11.59% 42.96B
+3.50%-4.15%+265.85%+484.30% 31.73B
-0.61%-3.11%+14.00%-12.36% 30.22B
-1.27%-7.02%-0.82%+20.47% 28.94B
-0.66%-5.84%+7.59%+12.76% 23.87B
+2.01%+3.57%+57.15%+128.55% 13.57B
+0.22%-0.65%+6.75%+8.29% 12.96B
+2.77%-1.48% - - 13.39B
+0.68%-1.74%+103.98%+81.60% 12.2B
Average +0.79%-2.36%+45.04%+68.74% 20.99B
Weighted average by Cap. +0.69%-2.40%+53.48%+92.81%

Financials

2026 *2027 *
Net sales 6.3M 5.46M 5.04M 4.72M 8.82M 603M 9M 60.07M 23.26M 291M 23.63M 23.12M 1.01B 19.14M 16.61M 15.31M 14.35M 26.81M 1.83B 27.36M 183M 70.71M 883M 71.86M 70.31M 3.07B
Net income -26.8M -23.26M -21.44M -20.09M -37.53M -2.57B -38.31M -256M -99.01M -1.24B -101M -98.44M -4.3B -18.45M -16.02M -14.76M -13.83M -25.84M -1.77B -26.38M -176M -68.18M -852M -69.28M -67.79M -2.96B
Net Debt - -
Logo Plus Therapeutics, Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Employees
28
Date Price Change Volume
26-06-11 5.420 $ +0.56% 76,745
26-06-10 5.390 $ -2.00% 126,285
26-06-09 5.500 $ -0.54% 108,493
26-06-08 5.530 $ +2.22% 145,129
26-06-05 5.410 $ -5.83% 120,356
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.420USD
Average target price
36.00USD
Spread / Average Target
+564.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSTV Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!